Gene Editing Shows Promise in Lowering Cholesterol, Potentially Reducing Reliance on Daily Medication

A new clinical trial published in The New England Journal of Medicine demonstrates that a single treatment using CRISPR gene-editing technology can significantly lower levels of “bad” cholesterol and triglycerides in adults whose cholesterol remains high despite conventional therapies.

Researchers presented the findings yesterday, November 9, 2025, at the American Heart Association’s annual meeting, detailing how they targeted the ANGPTL3 gene in the liver, effectively mimicking naturally occurring protective mutations. The trial participants experienced roughly a 50% reduction in LDL cholesterol and triglycerides within weeks of the one-time treatment. This breakthrough offers a potential alternative to lifelong medication for some patients, though further research is needed.

The study involved a small group of individuals, and scientists caution that long-term safety monitoring is crucial. While not yet widely available, this approach represents a shift toward potentially correcting the root causes of high cholesterol rather than simply managing the symptoms. Understanding your risk factors for high cholesterol is an important first step in preventative care. Heart disease remains the leading cause of death globally, impacting millions of families each year.

Experts emphasize that healthy lifestyle choices – including diet, exercise, and stress management – remain foundational to cardiovascular health, even with advancements in gene editing. The National Heart, Lung, and Blood Institute offers resources on heart-healthy living. Researchers will continue to evaluate the durability of the treatment’s effects and expand trials to larger patient populations.